High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy

P. E. Macchia, M. Bagattini, G. Lupoli, M. Vitale, G. Vitale, G. Fenzi

Research output: Contribution to journalArticle

Abstract

In order to compare oral and high-dose iv corticosteroid therapy for Graves' disease, 25 patients with Graves' ophthalmopathy were treated with two weekly iv injections of 1g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks, and were compared to a group of 26 patients treated with oral prednisone at a dose of 60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months. The efficacy of treatment was evaluated using the ophthalmopathy index score. Patients were followed at 3, 6, 12 months, and afterwards yearly. All patients showed a significant improvement in signs and symptoms of orbital inflammation and a slight improvement in proptosis and diplopia. Relevant side-effects were reported from patients receiving oral therapy, but no significant side-effects were observed in patients treated with high iv doses; a few cases presented with gastric pain (highly sensitive to aluminium oxide or ranitidine), while most of the patients referred to cutaneous rashes and a metal taste that disappeared some hours after the infusion. Improvements observed after treatment have been stable in both groups. In conclusion, in addition to a lower incidence of side-effects compared to the classic oral therapy, the high-dose iv steroid therapy provides efficient and stable improvement in Graves' ophthalmopathy.

Original languageEnglish
Pages (from-to)152-158
Number of pages7
JournalJournal of Endocrinological Investigation
Volume24
Issue number3
Publication statusPublished - 2001

Fingerprint

Graves Ophthalmopathy
Adrenal Cortex Hormones
Therapeutics
Ranitidine
Exophthalmos
Diplopia
Aluminum Oxide
Graves Disease
Methylprednisolone
Prednisone
Exanthema
Signs and Symptoms
Stomach
Metals
Steroids
Inflammation
Pain
Injections
Incidence

Keywords

  • Adverse effects
  • Autoimmune response/disease
  • Corticosteroids
  • Graves' disease
  • Intravenous administration and dosage
  • Thyroid gland/hyperthyroidism

ASJC Scopus subject areas

  • Endocrinology

Cite this

Macchia, P. E., Bagattini, M., Lupoli, G., Vitale, M., Vitale, G., & Fenzi, G. (2001). High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. Journal of Endocrinological Investigation, 24(3), 152-158.

High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. / Macchia, P. E.; Bagattini, M.; Lupoli, G.; Vitale, M.; Vitale, G.; Fenzi, G.

In: Journal of Endocrinological Investigation, Vol. 24, No. 3, 2001, p. 152-158.

Research output: Contribution to journalArticle

Macchia, PE, Bagattini, M, Lupoli, G, Vitale, M, Vitale, G & Fenzi, G 2001, 'High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy', Journal of Endocrinological Investigation, vol. 24, no. 3, pp. 152-158.
Macchia, P. E. ; Bagattini, M. ; Lupoli, G. ; Vitale, M. ; Vitale, G. ; Fenzi, G. / High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. In: Journal of Endocrinological Investigation. 2001 ; Vol. 24, No. 3. pp. 152-158.
@article{cae1871c65704e6bb1a4d30c079ea2ea,
title = "High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy",
abstract = "In order to compare oral and high-dose iv corticosteroid therapy for Graves' disease, 25 patients with Graves' ophthalmopathy were treated with two weekly iv injections of 1g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks, and were compared to a group of 26 patients treated with oral prednisone at a dose of 60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months. The efficacy of treatment was evaluated using the ophthalmopathy index score. Patients were followed at 3, 6, 12 months, and afterwards yearly. All patients showed a significant improvement in signs and symptoms of orbital inflammation and a slight improvement in proptosis and diplopia. Relevant side-effects were reported from patients receiving oral therapy, but no significant side-effects were observed in patients treated with high iv doses; a few cases presented with gastric pain (highly sensitive to aluminium oxide or ranitidine), while most of the patients referred to cutaneous rashes and a metal taste that disappeared some hours after the infusion. Improvements observed after treatment have been stable in both groups. In conclusion, in addition to a lower incidence of side-effects compared to the classic oral therapy, the high-dose iv steroid therapy provides efficient and stable improvement in Graves' ophthalmopathy.",
keywords = "Adverse effects, Autoimmune response/disease, Corticosteroids, Graves' disease, Intravenous administration and dosage, Thyroid gland/hyperthyroidism",
author = "Macchia, {P. E.} and M. Bagattini and G. Lupoli and M. Vitale and G. Vitale and G. Fenzi",
year = "2001",
language = "English",
volume = "24",
pages = "152--158",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy

AU - Macchia, P. E.

AU - Bagattini, M.

AU - Lupoli, G.

AU - Vitale, M.

AU - Vitale, G.

AU - Fenzi, G.

PY - 2001

Y1 - 2001

N2 - In order to compare oral and high-dose iv corticosteroid therapy for Graves' disease, 25 patients with Graves' ophthalmopathy were treated with two weekly iv injections of 1g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks, and were compared to a group of 26 patients treated with oral prednisone at a dose of 60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months. The efficacy of treatment was evaluated using the ophthalmopathy index score. Patients were followed at 3, 6, 12 months, and afterwards yearly. All patients showed a significant improvement in signs and symptoms of orbital inflammation and a slight improvement in proptosis and diplopia. Relevant side-effects were reported from patients receiving oral therapy, but no significant side-effects were observed in patients treated with high iv doses; a few cases presented with gastric pain (highly sensitive to aluminium oxide or ranitidine), while most of the patients referred to cutaneous rashes and a metal taste that disappeared some hours after the infusion. Improvements observed after treatment have been stable in both groups. In conclusion, in addition to a lower incidence of side-effects compared to the classic oral therapy, the high-dose iv steroid therapy provides efficient and stable improvement in Graves' ophthalmopathy.

AB - In order to compare oral and high-dose iv corticosteroid therapy for Graves' disease, 25 patients with Graves' ophthalmopathy were treated with two weekly iv injections of 1g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks, and were compared to a group of 26 patients treated with oral prednisone at a dose of 60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months. The efficacy of treatment was evaluated using the ophthalmopathy index score. Patients were followed at 3, 6, 12 months, and afterwards yearly. All patients showed a significant improvement in signs and symptoms of orbital inflammation and a slight improvement in proptosis and diplopia. Relevant side-effects were reported from patients receiving oral therapy, but no significant side-effects were observed in patients treated with high iv doses; a few cases presented with gastric pain (highly sensitive to aluminium oxide or ranitidine), while most of the patients referred to cutaneous rashes and a metal taste that disappeared some hours after the infusion. Improvements observed after treatment have been stable in both groups. In conclusion, in addition to a lower incidence of side-effects compared to the classic oral therapy, the high-dose iv steroid therapy provides efficient and stable improvement in Graves' ophthalmopathy.

KW - Adverse effects

KW - Autoimmune response/disease

KW - Corticosteroids

KW - Graves' disease

KW - Intravenous administration and dosage

KW - Thyroid gland/hyperthyroidism

UR - http://www.scopus.com/inward/record.url?scp=0035067676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035067676&partnerID=8YFLogxK

M3 - Article

C2 - 11314743

AN - SCOPUS:0035067676

VL - 24

SP - 152

EP - 158

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 3

ER -